2023年7月28日，纪检监察机关配合开展全国医药领域腐败问题集中整治工作动员部署视频会议在北京召开，受到了全社会的广泛关注。2023年8月18日，《中国日报（CHINA DAILY）》记者就近日“纪检监察机关配合开展全国医药领域腐败问题”采访了我院胡晓东教授。

胡晓东教授认为，多年来，医疗保健领域的大多数反腐运动都集中在制药公司给医生回扣和患者给医生礼物等不法行为上。但这项最新调查的范围扩大到了医院院长、医院部门负责人和行政管理人员。这也说明了，在医院有两类人员最有可能产生腐败行为——有权分配资源的医院管理人员，以及开处方和制定治疗计划的普通医生。

胡晓东教授还认为，广东省反腐败部门8月1日披露了一起典型案件，这起案件表明，腐败行为会增加患者的支出，影响人们的幸福感、满意度和社会安全感。他认为，留住技术精湛的高端人员和购买高端设备需要花费大量资金，但政府提供的资金有限，医院为拥有或保持竞争优势，必须向市场要资源。随着医疗领域的市场化，医院也很容易被引诱选择提供额外“福利”的供应商。另一方面，对医院管理人员的监督和对市场价格的监督是不够的。医疗腐败是一个极其复杂的问题。尽管面临挑战，但这场运动应该坚定地推进，因为它也为重建医患关系和改革药品采购系统提供了机会。他认为，动员医院回归拯救生命和治疗人民疾病的公益职能，而不是以盈利为动力，这一点至关重要。政府、慈善组织和基金会可以共同努力，加大对医院的投资（以缓解财政压力）。

胡教授建议，对医院院长、科室负责人和普通医生等关键人员实施严格的监督是必要的，这样以确保他们的首要任务是提高医疗技能和解决疾病，而不是实现收入最大化。同时，增加医务工作者的奖金、福利以及各类补贴也很重要，同时培养他们健康的道德文化。另外，政府应该出台更多的规章制度来规范药品采购和销售程序，以及医疗产品的定价机制。应该投入更多的资金来支持生产利润率较低的基本药物企业。与此同时，可以推出优惠政策来支持制造商为有需要的患者生产更先进、价格也更高的药物。

英文版：

Hu Xiaodong, a professor at China University of Political Science and Law’s School of Political Science and Public Administration, said that over the years, most anti-corruption drives in the healthcare sector have centered on wrongdoing involving kickbacks given by pharmaceutical companies to doctors, and gifts from patients to doctors.

“But the scope of this latest investigation extends to hospital presidents and secretaries, heads of clinic departments and administrative officials. The form of corruption being investigated is also more varied,” he said.

Selling products at high prices is a common malpractice among pharmaceutical suppliers. These vastly inflated prices enable them to bribe hospital staff members.

Hu said a typical case was revealed by anti-corruption authorities in Guangdong province on Aug 1.

Hu said, “The case shows how corrupt acts can drive up expenses shouldered by patients and impact people’s sense of happiness, satisfaction and security in society.”

Hu said: “Retaining skilled healthcare workers and purchasing high-end equipment cost enormous amounts of money, but funds provided by governments are limited. With marketization of the medical field, hospitals are easily lured into choosing suppliers that offer additional benefits.”

He added that two groups are the most likely to commit offenses — hospital administrators who have the power to allocate resources, and doctors who write prescriptions and devise treatment plans.

“Supervision of hospital administrators and oversight of market prices are insufficient,” Hu said.

Hu said medical corruption is an extremely complicated issue. Despite challenges, the campaign should be press ahead firmly, as it also presents an opportunity to rebuild doctor-patient relationships and reform drug procurement systems.

“It is essential to mobilize hospitals to return to the function of saving lives and treating people’s ailments as public welfare, rather than being driven by making profits,” he said.

“Governments, charity organizations and foundations can join efforts to step up investment to hospitals (to ease financial pressure).”

Hu also suggested imposing stricter oversight of key shareholders, such as hospital presidents and secretaries, department heads and doctors, to ensure that their priority is to enhance medical skills and address illnesses, instead of maximizing income.

“It is also important to increase bonuses and housing subsidies for medical workers while nurturing a healthy ethical culture among them,” he said.

Hu added that more rules and regulations should be introduced to standardize drug procurement and sales procedures, and pricing mechanisms for medical products.

“More funds should be invested to support enterprises making basic medications that have a slim profit margin. In the meantime, favorable policies can be rolled out to support manufacturers creating more costly and advanced drugs for patients in need,” he said.